Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Recruiting · NCT05053607 · Registry updated 2024-12-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2024-12-11 | NCT05053607 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
| Pack Health | 3 |
| Sanofi | 254 |
| University of Washington | 397 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The University of Texas MD Anderson Cancer Center | Houston | United States | 1 |
| University of Washington | Seattle | United States | 36 |